Abstract
Purpose
Aspirin use is associated with reduced risk of, and death from, prostate cancer. Our aim was to determine whether low-dose aspirin use after a prostate cancer diagnosis was associated with reduced prostate cancer-specific mortality.
Methods
A cohort of newly diagnosed prostate cancer patients (1998–2006) was identified in the UK Clinical Practice Research Datalink (confirmed by cancer registry linkage). A nested case–control analysis was conducted using conditional logistic regression to compare aspirin usage in cases (prostate cancer deaths) with up to three controls (matched by age and year of diagnosis).
Results
Post-diagnostic low-dose aspirin use was identified in 52 % of 1,184 prostate cancer-specific deaths and 39 % of 3,531 matched controls (unadjusted OR 1.51, 95 % CI 1.19, 1.90; p < 0.001). After adjustment for confounders including treatment and comorbidities, this association was attenuated (adjusted OR 1.02 95 % CI 0.78, 1.34; p = 0.86). Adjustment for estrogen therapy accounted for the majority of this attenuation. There was also no evidence of dose–response association after adjustments. Compared with no use, patients with 1–11 prescriptions and 12 or more prescriptions had adjusted ORs of 1.07 (95 % CI 0.78, 1.47; p = 0.66) and 0.97 (95 % CI 0.69, 1.37; p = 0.88), respectively. There was no evidence of a protective association between low-dose aspirin use in the year prior to diagnosis and prostate cancer-specific mortality (adjusted OR 1.04 95 % CI 0.89, 1.22; p = 0.60).
Conclusion
We found no evidence of an association between low-dose aspirin use before or after diagnosis and risk of prostate cancer-specific mortality, after potential confounders were accounted for, in UK prostate cancer patients.
Similar content being viewed by others
References
NHS (2011) Prescriptions dispensed in the community, statistics for England—2000–2010. The NHS Information Centre, Prescribing and Primary Care Services
BNF (2012) British National Formulary: current edition. BMJ Group & Pharmaceutical Press, London
Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373:1301–1309
Wu KK (2000) Aspirin and salicylate: an old remedy with a new twist. Circulation 102:2022–2023
Pruthi RS, Wallen EM (2005) Cyclooxygenase-2: a therapeutic target for prostate cancer. Clin Genitourin Cancer. 4:203–211
Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 61:46–52
Nash GF, Turner LF, Scully MF, Kakkar AK (2002) Platelets and cancer. Lancet Oncol. 3:425–430
Jain S, Harris J, Ware J (2010) Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 30:2362–2367
Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T et al (2007) The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 170:1337–1347
Bambace NM, Holmes CE (2011) The platelet contribution to cancer progression. J Thromb Haemost 9:237–249
Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31–41
Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G et al (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602–1612
Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C (2012) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23:1403–1415
Norrish AE, Jackson RT, McRae CU (1998) Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 77:511–515
Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC et al (2002) Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 11:1108–1111
Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL (2011) Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988–2006. Int J Cancer 128:2444–2452
Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM (2012) Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer Prev Res (Phila). 5:1223–1228
Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL (2012) Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol
Grytli HH, Fagerland MW, Fossa SD, Tasken KA (2013) Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol
Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302:766–768
NCI (2012) SEER training modules, prostate cancer. Morphology & Grade 2012 27/11/2012; Available from: http://training.seer.cancer.gov/prostate/abstract-code-stage/morphology.html
Khan NF, Perera R, Harper S, Rose PW (2010) Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 11:1
Levesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087
Etminan M, Samii A (2004) Pharmacoepidemiology I. A review of pharmacoepidemiologic study designs. Pharmacotherapy. 24:964–969
Fine J, Gray R (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509
Bosset PO, Albiges L, Seisen T, de la Motte Rouge T, Phe V, Bitker MO et al (2012) Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU Int 110:E826–E829
Moore AL, Dimitropoulou P, Lane A, Powell PH, Greenberg DC, Brown CH et al (2009) Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int. 104:1592–1598
Bannon F, Gavin AT (2009) Monitoring care of prostate cancer patients in Northern Ireland diagnosed 2006 (with comparison 1996 & 2001). Northern Ireland Cancer Registry, Belfast
Fujisawa M, Miyake H (2008) Significance of micrometastases in prostate cancer. Surg Oncol 17:247–252
Cardwell CR, Suissa S, Murray LJ (2013) Re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer–specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 64:e10
Bedson J, Whitehurst T, Lewis M, Croft P (2001) Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. Br J Gen Pract 51:1001–1003
Yang YX, Hennessy S, Propert K, Hwang WT, Sarkar M, Lewis JD (2008) Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf 17:869–876
Yood MU, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE et al (2007) Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 16:961–968
Choe KS, Correa D, Jani AB, Liauw SL (2010) The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer 116:1820–1826
Acknowledgments
This study is based on part of the data from the General Practice Research Database obtained under license from the UK Medicines and Healthcare Regulatory Agency. This work was supported by a Cancer Research-UK Project Grant (C19630/A13265). CRC was supported by a Health and Social Care Research and Development, Public Health Agency, Northern Ireland, funded by UK National Institute for Health Research Career Development Fellowship. EMF is supported by a PhD studentship from the Irish Cancer Society (CRS10FLA). The funders had no role in the study design; collection, analysis, and interpretation of the data; writing of the report; or the decision to submit for publication.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cardwell, C.R., Flahavan, E.M., Hughes, C.M. et al. Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. Cancer Causes Control 25, 33–43 (2014). https://doi.org/10.1007/s10552-013-0306-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-013-0306-x